Nasdaq · CIK 0001639691
LIVN LivaNova PLC
Insider trading from SEC Form 4. Last filing 27 d ago. Close $76.39 on Oct 9, 2026, +54% from the 52-week low and -10% from the high.
Last 90 days
Net insider value
-$592k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
3
$592k by 2 insiders
Insiders on file
18
with a Form 4 at this company
Price and insider trades, last year
LIVNOct 9, 2026 · close 76.39
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at LivaNova PLC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 46Moderate | Francesco Bianchi director sell | $273k 3,500 shares | -44% | +58% from low-8% from high | |
| 40Moderate | Brooke Story director sell | $187k 2,300 shares | -23% | +65% from low-4% from high | |
| 39Weak | Francesco Bianchi director sell | $132k 1,650 shares | -17% | +61% from low-6% from high | |
| 15Weak | Francesco Bianchi director sell | $96k 1,200 shares | -11% | +94% from low-0% from high | |
| 31Weak | Francesco Bianchi director sell | $136k 1,800 shares | -20% | +83% from low0% from high | |
| 15Weak | Brooke Story director sell | $13k 250 shares | -4% | +59% from low-8% from high | |
| 29Weak | Francesco Bianchi director sell | $85k 1,500 shares | -14% | +66% from low0% from high | |
| 28Weak | Francesco Bianchi director sell | $64k 1,250 shares | -14% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 11, 2024 | Bianchi Francesco Director | 1,250 0.00% of outstanding | $64k | Dec 11, 2024 | none |
| Dec 10, 2024 | Hebbelinck Trui Officer | 6,000 0.01% of outstanding | $302k | Dec 10, 2024 | none |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Anne M. Liddy Chief Legal Officer | AGrant or award Restricted Stock Unitsderivative | +6,291 | $0.00 | $0 | 6,291 | 27 d ago |
| Sep 10, 2026 | Francesco Bianchi director | SOpen-market sale Ordinary Shares | -3,500 | $78.01 | $273k | 4,434 | 29 d ago |
| Sep 4, 2026 | Brooke Story director | SOpen-market sale Ordinary Shares | -2,300 | $81.42 | $187k | 7,488 | 35 d ago |
| Aug 31, 2026 | Francesco Bianchi director | SOpen-market sale Ordinary Shares | -1,650 | $79.72 | $132k | 7,934 | 41 d ago |
| Jun 15, 2026 | James Christopher Barry director | MOption exercise Ordinary Shares | +4,042 | $0.00 | $0 | 8,404 | Jun 17, 2026 |
| Jun 15, 2026 | Francesco Bianchi director | MOption exercise Ordinary Shares | +4,042 | $0.00 | $0 | 11,270 | Jun 17, 2026 |
| Jun 15, 2026 | Francesco Bianchi director | FTax withholding Ordinary Shares | -486 | $79.70 | $39k | 10,784 | Jun 17, 2026 |
| Jun 15, 2026 | James Christopher Barry director | FTax withholding Ordinary Shares | -486 | $79.70 | $39k | 7,918 | Jun 17, 2026 |
| Jun 15, 2026 | Francesco Bianchi director | SOpen-market sale Ordinary Shares | -1,200 | $80.19 | $96k | 9,584 | Jun 17, 2026 |
| Jun 15, 2026 | James Christopher Barry director | MOption exercise Restricted Stock Unitsderivative | -4,042 | $0.00 | $0 | 0 | Jun 17, 2026 |
| Jun 15, 2026 | Francesco Bianchi director | MOption exercise Restricted Stock Unitsderivative | -4,042 | $0.00 | $0 | 0 | Jun 17, 2026 |
| Jun 15, 2026 | James Christopher Barry director | AGrant or award Restricted Stock Unitsderivative | +2,383 | $0.00 | $0 | 2,383 | Jun 17, 2026 |
| Jun 15, 2026 | Francesco Bianchi director | AGrant or award Restricted Stock Unitsderivative | +2,383 | $0.00 | $0 | 2,383 | Jun 17, 2026 |
| May 26, 2026 | Francesco Bianchi director | SOpen-market sale Ordinary Shares | -1,800 | $75.75 | $136k | 7,228 | May 27, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | MOption exercise Ordinary Shares | +17,815 | $0.00 | $0 | 30,566 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | FTax withholding Ordinary Shares | -8,377 | $61.27 | $513k | 22,189 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | MOption exercise Restricted Stock Unitsderivative | -457 | $0.00 | $0 | 0 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | MOption exercise Restricted Stock Unitsderivative | -1,330 | $0.00 | $0 | 1,329 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | MOption exercise Restricted Stock Unitsderivative | -1,229 | $0.00 | $0 | 2,457 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | MOption exercise Restricted Stock Unitsderivative | -2,343 | $0.00 | $0 | 4,684 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | MOption exercise Performance Stock Unitsderivative | -3,243 | $0.00 | $0 | 0 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | MOption exercise Performance Stock Unitsderivative | -3,156 | $0.00 | $0 | 0 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | MOption exercise Performance Stock Unitsderivative | -6,057 | $0.00 | $0 | 0 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | AGrant or award Restricted Stock Unitsderivative | +8,976 | $0.00 | $0 | 8,976 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | AGrant or award Performance Stock Unitsderivative | +2,992 | $0.00 | $0 | 2,992 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | AGrant or award Performance Stock Unitsderivative | +2,992 | $0.00 | $0 | 2,992 | Apr 1, 2026 |
| Mar 30, 2026 | Stephanie Bolton President, Global Epilepsy | AGrant or award Performance Stock Unitsderivative | +2,992 | $0.00 | $0 | 2,992 | Apr 1, 2026 |
| Mar 11, 2026 | Franco Poletti President, Cardiopulmonary | MOption exercise Ordinary Shares | +2,140 | $57.60 | $123k | 10,990 | Mar 13, 2026 |
| Mar 11, 2026 | Franco Poletti President, Cardiopulmonary | FTax withholding Ordinary Shares | -1,980 | $62.26 | $123k | 9,010 | Mar 13, 2026 |
| Mar 11, 2026 | Franco Poletti President, Cardiopulmonary | FTax withholding Ordinary Shares | -69 | $62.26 | $4,296 | 8,941 | Mar 13, 2026 |
| Mar 11, 2026 | Franco Poletti President, Cardiopulmonary | MOption exercise Stock Appreciation Rightsderivative | -2,140 | $0.00 | $0 | 0 | Mar 13, 2026 |
| Dec 15, 2025 | Franco Poletti President, Cardiopulmonary | MOption exercise Ordinary Shares | +967 | $0.00 | $0 | 9,266 | Dec 17, 2025 |
| Dec 15, 2025 | Michael Damon Hutchinson SVP, CLO and Company Secretary | MOption exercise Ordinary Shares | +2,254 | $0.00 | $0 | 7,920 | Dec 17, 2025 |
| Dec 15, 2025 | Susan M Podlogar director | MOption exercise Ordinary Shares | +2,355 | $0.00 | $0 | 2,355 | Dec 17, 2025 |
| Dec 15, 2025 | Franco Poletti President, Cardiopulmonary | FTax withholding Ordinary Shares | -416 | $63.06 | $26k | 8,850 | Dec 17, 2025 |
| Dec 15, 2025 | Susan M Podlogar director | FTax withholding Ordinary Shares | -269 | $63.06 | $17k | 2,086 | Dec 17, 2025 |
| Dec 15, 2025 | Michael Damon Hutchinson SVP, CLO and Company Secretary | FTax withholding Ordinary Shares | -1,122 | $63.06 | $71k | 6,798 | Dec 17, 2025 |
| Dec 15, 2025 | Michael Damon Hutchinson SVP, CLO and Company Secretary | MOption exercise Restricted Stock Unitsderivative | -2,254 | $0.00 | $0 | 2,253 | Dec 17, 2025 |
| Dec 15, 2025 | Susan M Podlogar director | MOption exercise Restricted Stock Unitsderivative | -2,355 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 15, 2025 | Franco Poletti President, Cardiopulmonary | MOption exercise Restricted Stock Unitsderivative | -967 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Nov 18, 2025 | Brooke Story director | SOpen-market sale Ordinary Shares | -250 | $53.94 | $13k | 6,232 | Nov 19, 2025 |
| Sep 15, 2025 | Franco Poletti President, Cardiopulmonary | MOption exercise Ordinary Shares | +643 | $0.00 | $0 | 8,576 | Sep 17, 2025 |
| Sep 15, 2025 | Donald Zurbay director | AGrant or award Restricted Stock Unitsderivative | +2,560 | $0.00 | $0 | 2,560 | Sep 17, 2025 |
| Sep 15, 2025 | Franco Poletti President, Cardiopulmonary | FTax withholding Ordinary Shares | -277 | $55.43 | $15k | 8,299 | Sep 17, 2025 |
| Sep 15, 2025 | Franco Poletti President, Cardiopulmonary | MOption exercise Restricted Stock Unitsderivative | -643 | $0.00 | $0 | 1,932 | Sep 17, 2025 |
| Aug 25, 2025 | Francesco Bianchi director | SOpen-market sale Ordinary Shares | -1,500 | $56.50 | $85k | 9,028 | Aug 27, 2025 |
| Jun 15, 2025 | Ahmet Tezel Chief Innovation Officer | MOption exercise Ordinary Shares | +2,967 | $0.00 | $0 | 2,967 | Jun 17, 2025 |
| Jun 15, 2025 | Peter M Wilver director | MOption exercise Ordinary Shares | +3,416 | $0.00 | $0 | 7,148 | Jun 17, 2025 |
| Jun 15, 2025 | Brooke Story director | MOption exercise Ordinary Shares | +3,416 | $0.00 | $0 | 6,892 | Jun 17, 2025 |
| Jun 15, 2025 | Todd C Schermerhorn director | MOption exercise Ordinary Shares | +3,416 | $0.00 | $0 | 9,473 | Jun 17, 2025 |
| Jun 15, 2025 | Sharon O'Kane director | MOption exercise Ordinary Shares | +3,416 | $0.00 | $0 | 12,910 | Jun 17, 2025 |
| Jun 15, 2025 | James Christopher Barry director | MOption exercise Ordinary Shares | +3,416 | $0.00 | $0 | 4,772 | Jun 17, 2025 |
| Jun 15, 2025 | Francesco Bianchi director | MOption exercise Ordinary Shares | +3,416 | $0.00 | $0 | 10,938 | Jun 17, 2025 |
| Jun 15, 2025 | Seng Stacy Enxing director | MOption exercise Ordinary Shares | +3,416 | $0.00 | $0 | 12,161 | Jun 17, 2025 |
| Jun 15, 2025 | William A Kozy director | MOption exercise Ordinary Shares | +4,840 | $0.00 | $0 | 33,148 | Jun 17, 2025 |
| Jun 15, 2025 | Susan M Podlogar director | AGrant or award Restricted Stock Unitsderivative | +4,042 | $0.00 | $0 | 4,042 | Jun 17, 2025 |
| Jun 15, 2025 | Ahmet Tezel Chief Innovation Officer | FTax withholding Ordinary Shares | -1,032 | $45.76 | $47k | 1,935 | Jun 17, 2025 |
| Jun 15, 2025 | Peter M Wilver director | FTax withholding Ordinary Shares | -410 | $45.76 | $19k | 6,738 | Jun 17, 2025 |
| Jun 15, 2025 | Brooke Story director | FTax withholding Ordinary Shares | -410 | $45.76 | $19k | 6,482 | Jun 17, 2025 |
| Jun 15, 2025 | Todd C Schermerhorn director | FTax withholding Ordinary Shares | -410 | $45.76 | $19k | 9,063 | Jun 17, 2025 |
| Jun 15, 2025 | Sharon O'Kane director | FTax withholding Ordinary Shares | -1,606 | $45.76 | $73k | 11,304 | Jun 17, 2025 |
| Jun 15, 2025 | James Christopher Barry director | FTax withholding Ordinary Shares | -410 | $45.76 | $19k | 4,362 | Jun 17, 2025 |
| Jun 15, 2025 | Francesco Bianchi director | FTax withholding Ordinary Shares | -410 | $45.76 | $19k | 10,528 | Jun 17, 2025 |
| Jun 15, 2025 | Seng Stacy Enxing director | FTax withholding Ordinary Shares | -410 | $45.76 | $19k | 11,751 | Jun 17, 2025 |
| Jun 15, 2025 | William A Kozy director | FTax withholding Ordinary Shares | -581 | $45.76 | $27k | 32,567 | Jun 17, 2025 |
| Jun 15, 2025 | Ahmet Tezel Chief Innovation Officer | MOption exercise Restricted Stock Unitsderivative | -2,967 | $0.00 | $0 | 8,896 | Jun 17, 2025 |
| Jun 15, 2025 | Peter M Wilver director | MOption exercise Restricted Stock Unitsderivative | -3,416 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 15, 2025 | Brooke Story director | MOption exercise Restricted Stock Unitsderivative | -3,416 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 15, 2025 | Todd C Schermerhorn director | MOption exercise Restricted Stock Unitsderivative | -3,416 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 15, 2025 | Sharon O'Kane director | MOption exercise Restricted Stock Unitsderivative | -3,416 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 15, 2025 | James Christopher Barry director | MOption exercise Restricted Stock Unitsderivative | -3,416 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 15, 2025 | Francesco Bianchi director | MOption exercise Restricted Stock Unitsderivative | -3,416 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 15, 2025 | Seng Stacy Enxing director | MOption exercise Restricted Stock Unitsderivative | -3,416 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 15, 2025 | William A Kozy director | MOption exercise Restricted Stock Unitsderivative | -4,840 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Jun 15, 2025 | Peter M Wilver director | AGrant or award Restricted Stock Unitsderivative | +4,042 | $0.00 | $0 | 4,042 | Jun 17, 2025 |
| Jun 15, 2025 | Brooke Story director | AGrant or award Restricted Stock Unitsderivative | +4,042 | $0.00 | $0 | 4,042 | Jun 17, 2025 |
| Jun 15, 2025 | Todd C Schermerhorn director | AGrant or award Restricted Stock Unitsderivative | +4,042 | $0.00 | $0 | 4,042 | Jun 17, 2025 |
| Jun 15, 2025 | Sharon O'Kane director | AGrant or award Restricted Stock Unitsderivative | +4,042 | $0.00 | $0 | 4,042 | Jun 17, 2025 |
| Jun 15, 2025 | James Christopher Barry director | AGrant or award Restricted Stock Unitsderivative | +4,042 | $0.00 | $0 | 4,042 | Jun 17, 2025 |
| Jun 15, 2025 | Francesco Bianchi director | AGrant or award Restricted Stock Unitsderivative | +4,042 | $0.00 | $0 | 4,042 | Jun 17, 2025 |
| Jun 15, 2025 | Seng Stacy Enxing director | AGrant or award Restricted Stock Unitsderivative | +4,042 | $0.00 | $0 | 4,042 | Jun 17, 2025 |
| Jun 15, 2025 | William A Kozy director | AGrant or award Restricted Stock Unitsderivative | +5,681 | $0.00 | $0 | 5,681 | Jun 17, 2025 |
| Mar 30, 2025 | Stephanie Bolton President, Global Epilepsy | MOption exercise Ordinary Shares | +6,024 | $0.00 | $0 | 15,586 | Apr 1, 2025 |
| Mar 30, 2025 | Vladimir Makatsaria Chief Executive Officer | MOption exercise Ordinary Shares | +9,330 | $0.00 | $0 | 9,330 | Apr 1, 2025 |
| Mar 30, 2025 | Alex Shvartsburg Chief Financial Officer | MOption exercise Ordinary Shares | +11,083 | $0.00 | $0 | 30,196 | Apr 1, 2025 |
| Mar 30, 2025 | Natalia Kozmina Chief Human Resources Officer | AGrant or award Restricted Stock Unitsderivative | +12,777 | $0.00 | $0 | 12,777 | Apr 1, 2025 |
| Mar 30, 2025 | Ahmet Tezel Chief Innovation Officer | AGrant or award Restricted Stock Unitsderivative | +10,222 | $0.00 | $0 | 10,222 | Apr 1, 2025 |
| Mar 30, 2025 | Franco Poletti President, Cardiopulmonary | MOption exercise Ordinary Shares | +1,257 | $0.00 | $0 | 8,475 | Apr 1, 2025 |
| Mar 30, 2025 | William A Kozy director | MOption exercise Ordinary Shares | +1,034 | $0.00 | $0 | 28,496 | Apr 1, 2025 |
| Mar 30, 2025 | Michael Damon Hutchinson Chief Legal Officer | MOption exercise Ordinary Shares | +2,930 | $0.00 | $0 | 6,686 | Apr 1, 2025 |
| Mar 30, 2025 | Natalia Kozmina Chief Human Resources Officer | AGrant or award Restricted Stock Unitsderivative | +6,388 | $0.00 | $0 | 6,388 | Apr 1, 2025 |
| Mar 30, 2025 | Stephanie Bolton President, Global Epilepsy | FTax withholding Ordinary Shares | -2,835 | $39.13 | $111k | 12,751 | Apr 1, 2025 |
| Mar 30, 2025 | Michael Damon Hutchinson Chief Legal Officer | FTax withholding Ordinary Shares | -1,020 | $39.13 | $40k | 5,666 | Apr 1, 2025 |
| Mar 30, 2025 | Ahmet Tezel Chief Innovation Officer | AGrant or award Performance Stock Unitsderivative | +5,111 | $0.00 | $0 | 5,111 | Apr 1, 2025 |
| Mar 30, 2025 | Vladimir Makatsaria Chief Executive Officer | FTax withholding Ordinary Shares | -5,046 | $39.13 | $197k | 4,284 | Apr 1, 2025 |
| Mar 30, 2025 | Alex Shvartsburg Chief Financial Officer | FTax withholding Ordinary Shares | -3,516 | $39.13 | $138k | 26,680 | Apr 1, 2025 |
| Mar 30, 2025 | Franco Poletti President, Cardiopulmonary | FTax withholding Ordinary Shares | -542 | $39.13 | $21k | 7,933 | Apr 1, 2025 |
| Mar 30, 2025 | William A Kozy director | FTax withholding Ordinary Shares | -188 | $39.13 | $7,356 | 28,308 | Apr 1, 2025 |
| Mar 30, 2025 | Stephanie Bolton President, Global Epilepsy | MOption exercise Restricted Stock Unitsderivative | -426 | $0.00 | $0 | 0 | Apr 1, 2025 |
| Mar 30, 2025 | Michael Damon Hutchinson Chief Legal Officer | MOption exercise Restricted Stock Unitsderivative | -1,477 | $0.00 | $0 | 2,955 | Apr 1, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- James Christopher Barrydirector
- Francesco Bianchidirector
- Stephanie BoltonPresident, Global Epilepsy
- Seng Stacy Enxingdirector
- Michael Damon HutchinsonSVP, CLO and Company Secretary
- William A Kozydirector
- Natalia KozminaChief Human Resources Officer
- Anne M. LiddyChief Legal Officer
- Vladimir MakatsariaChief Executive Officer
- Sharon O'Kanedirector
- Susan M Podlogardirector
- Franco PolettiPresident, Cardiopulmonary
- Todd C Schermerhorndirector
- Alex ShvartsburgChief Financial Officer
- Brooke Storydirector
- Ahmet TezelChief Innovation Officer
- Peter M Wilverdirector
- Donald Zurbayceo, president, officer, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.